Cargando…

In response to: Treatment of patients with multiple myeloma progressing on frontline therapy with lenalidomide, Moreau et al., 2019

Detalles Bibliográficos
Autores principales:	Klippel, Zandra, Kimball, Amy, Tekle, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863861/ https://www.ncbi.nlm.nih.gov/pubmed/31745070 http://dx.doi.org/10.1038/s41408-019-0250-4

Ejemplares similares

Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
por: Moreau, Philippe, et al.
Publicado: (2019)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
por: Dhanasiri, Sujith
Publicado: (2019)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

Gustave Moreau /
por: Selz, Jean
Publicado: (1979)

Bortezomib, Lenalidomide and Dexamethasone as Induction Therapy Prior to Autologous Transplantation in Multiple Myeloma: The More Is Likely the Better
por: Mohty, Mohamad, et al.
Publicado: (2020)

Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
por: Nooka, Ajay K., et al.
Publicado: (2022)

Variants of Moreau's sweeping process
por: Siddiqui, A H, et al.
Publicado: (2001)

Revisiting the Island of Doctor Moreau
por: Breedlove, Byron
Publicado: (2021)

Capt. Victor Moreau Rice
Publicado: (1918)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
por: Andersen, Kristian T., et al.
Publicado: (2020)

La isla del Doctor Moreau
por: Wells, H. G. (Herbert George), 1866-1946
Publicado: (1979)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
por: Biran, Noa, et al.
Publicado: (2019)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Early lessons from the frontline of the 2019-nCoV outbreak
por: Zhang, Hong
Publicado: (2020)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation
por: Derman, Benjamin A., et al.
Publicado: (2021)

Cytomegalovirus Retinitis Associated with Lenalidomide Use for Multiple Myeloma in an Immunocompetent Patient
por: Adams, Matthew K., et al.
Publicado: (2019)

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.
por: Romagnoli, Micaela, et al.
Publicado: (2019)

P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
por: Moreau, Philippe, et al.
Publicado: (2023)

Reply by Gattinoni et al. to Hedenstierna et al., to Maley et al., to Fowler et al., to Bhatia and Mohammed, to Bos, to Koumbourlis and Motoyama, and to Haouzi et al.
por: Gattinoni, Luciano, et al.
Publicado: (2020)

Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple Myeloma
por: Alegre, Adrian, et al.
Publicado: (2011)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
por: de Arriba de la Fuente, Felipe, et al.
Publicado: (2022)

SUMOylation inhibition enhances multiple myeloma sensitivity to lenalidomide
por: Du, Li, et al.
Publicado: (2022)

Alicia Moreau de Justo : pionera del feminismo y la igualdad
por: López, Gladys, 1966-

Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2011)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.
por: Raghu, Ganesh, et al.
Publicado: (2022)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Reply to Chase et al. and to Milner et al.
por: Mittel, Aaron M., et al.
Publicado: (2020)

Reply by Xu et al. to Haouzi et al.
por: Xu, Yonghao, et al.
Publicado: (2020)

Reply by Pan et al. to Haouzi et al.
por: Pan, Chun, et al.
Publicado: (2020)

Reply to Topeli et al. and to Akinosoglou et al.
por: Azevedo, Luciano C. P., et al.
Publicado: (2020)

Reply to Turnbull et al. and to Hulme et al.
por: Breuer, Oded, et al.
Publicado: (2020)

Reply to Shoemark et al. and to Shapiro et al.
por: Amirav, Israel, et al.
Publicado: (2020)

Reply to Gueret et al. and to Hammond et al.
por: Brown, Ryan M., et al.
Publicado: (2020)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e0qgakppin5ieh03tsnl39clnk